Source-grounded facts extracted from REGENXBIO Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
REGENXBIO Inc. shareholders rejected Stock Option Exchange Program for executive employees at the 2026-05-29 meeting.
“Proposal 5 : By the following vote, the stockholders did not approve, a Stock Option Exchange Program for the Company’s executive employees: Votes For Votes Against Votes Abstaining Broker Non-Votes 14,097,815 21,021,531 145,416 7,554,121”
REGENXBIO Inc. shareholders approved Approval of Stock Option Exchange Program for non-executive employees at the 2026-05-29 meeting.
“Proposal 4 : By the following vote, the stockholders approved, the Stock Option Exchange Program for the Company’s non-executive employees: Votes For Votes Against Votes Abstaining Broker Non-Votes 26,352,456 8,853,230 59,076 7,554,121”
REGENXBIO Inc. shareholders approved Advisory vote to approve compensation of named executive officers at the 2026-05-29 meeting.
“Proposal 3 : By the following vote, the stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement: Votes For Votes Against Votes Abstaining Broker Non-Votes 32,392,302 2,722,825 149,635 7,554,121”
REGENXBIO Inc. shareholders approved Ratification of appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for year ending December 31, 2026 at the 2026-05-29 meeting.
“Proposal 2 : By the following vote, the stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026: Votes For Votes Against Votes Abstaining Broker Non-Votes 42,526,553 244,785 47,545 0”
REGENXBIO Inc. shareholders approved Election of three Class II directors at the 2026-05-29 meeting.
“Proposal 1 : By the following vote, the following three persons were elected to serve as Class II directors until the Company’s 2029 annual meeting of stockholders: Nominee Votes For Votes Withheld Broker Non-Votes Jean Bennett, M.D., Ph.D. 24,025,836 11,238,926 7,554,121 A.N. “Jerry” Karabelas, Ph.D. 27,124,923 8,139,839 7,554,121 Daniel Tassé 32,039,753 3,225,009 7,554,121”
REGENXBIO Inc. reported the first quarter ended March 31, 2026 results: revenue $6.4 million.
“announced settlement agreement with GlaxoSmithKline in March 2026, and is otherwise generally consistent with historical first quarter cash spend. Revenues: Revenues were $6.4 million for the three months ended March 31, 2026, compared to $89.0 million for the three months ended March 31, 2025. The decrease was primarily attributable to $70.0 million of”
REGENXBIO Inc. entered into Settlement and Release Agreement with GlaxoSmithKline LLC valued at $10.0 million (effective 2026-03-18).
“On March 18, 2026, REGENXBIO Inc. (the “Company”) entered into a Settlement and Release Agreement (the “Settlement Agreement”) with GlaxoSmithKline LLC (“GSK”) to resolve non-binding mediation related to the License Agreement dated March 6, 2009, as amended on April 15, 2009, between GSK and the Company (as amended, the “GSK-REGENXBIO Sublicense”).”
REGENXBIO Inc. reported financial results for the fourth quarter and year ended December 31, 2025.
“REGENXBIO Inc. (the “Company”) issued a press release regarding its results of operations and financial condition for the quarter and year ended December 31, 2025.”
REGENXBIO Inc. incurred loan of up to $250 million with an affiliate of HealthCare Royalty Management, LLC at 9.75% plus the 3-month secured overnight financing rate as administered by the F maturing the earlier of (i) 10 years after the Closing Date or (ii) the date on which the Royalty Bond has been fully repaid within ten years after the Closing Date, unl.
“affiliate of HealthCare Royalty Management, LLC (“HCRx”). Under the terms of the Loan Agreement, HCRx will provide REGENXBIO RS with an aggregate limited recourse loan of up to $250 million (the “Royalty Bond”). The Royalty Bond will be disbursed in three tranches, with $150 million already funded on the Closing Date, $50 million available if sales of a specified”
Vittal Vasista resigned as Executive Vice President, Chief Financial Officer and Principal Accounting Officer at REGENXBIO Inc..
“the Board accepted the resignation of Vittal Vasista from his position as Executive Vice President, Chief Financial Officer and Principal Accounting Officer, effective as of September 16, 2024”
Mitchell Chan was appointed as Executive Vice President, Chief Financial Officer and Principal Accounting Officer at REGENXBIO Inc..
“On September 16, 2024, the board of directors (the “Board” of REGENXBIO Inc. (the “Company”) appointed Mitchell Chan as Executive Vice President, Chief Financial Officer and Principal Accounting Officer, effective immediately.”
Jerry Karabelas departed as Lead Independent Director at REGENXBIO Inc..
“Daniel Tassé was appointed as the Company's Lead Independent Director, succeeding Jerry Karabelas.”
Daniel Tassé was appointed as Lead Independent Director at REGENXBIO Inc..
“Daniel Tassé was appointed as the Company's Lead Independent Director, succeeding Jerry Karabelas.”
Curran M. Simpson was appointed as Class I director at REGENXBIO Inc..
“In connection with his appointment, the Board appointed Mr. Simpson as a Class I director, effective July 1, 2024”
Curran M. Simpson was appointed as President and Chief Executive Officer at REGENXBIO Inc..
“the Company also announced that the Board appointed Curran M. Simpson as President and Chief Executive Officer, effective as of July 1, 2024.”
Kenneth T. Mills was appointed as Chairman of the Board at REGENXBIO Inc..
“accepted the resignation of Kenneth T. Mills from his position as President and Chief Executive Officer of the Company, effective July 1, 2024.”
REGENXBIO Inc. reported the first quarter ending March 31, 2024 results: revenue $15.6 million.
“and pre-funded warrants completed in March 2024, and was partially offset by cash used to fund operating activities during the first quarter of 2024. Revenues: Revenues were $15.6 million for the three months ended March 31, 2024, compared to $19.1 million for the three months ended March 31, 2023. The decrease was primarily attributable to non-recurring”
REGENXBIO Inc. reported financial results for third quarter ended September 30, 2023.
“REGENXBIO Inc. (the “Company”) issued a press release regarding its results of operations and financial condition for the quarter ended September 30, 2023.”
REGENXBIO Inc. shareholders approved Advisory vote to approve named executive officer compensation at the 2023-06-02 meeting.
“Proposal 3 : By the following vote, the stockholders approved, on an advisory basis,the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement: Votes For Votes Against Votes Abstaining Broker Non-Votes 36,733,345 1,131,884 111,321 1,965,878”
REGENXBIO Inc. shareholders approved Ratification of appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm at the 2023-06-02 meeting.
“Proposal 2 : By the following vote, the stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023: Votes For Votes Against Votes Abstaining Broker Non-Votes 39,799,734 50,694 92,000 0”
REGENXBIO Inc. shareholders approved Election of three Class II directors at the 2023-06-02 meeting.
“Proposal 1 : By the following vote, the following three persons were elected to serve as Class II directors until the Company’s 2026 annual meeting of stockholders: Nominee Votes For Votes Withheld Broker Non-Votes Jean Bennett, M.D., Ph.D. 30,318,877 7,665,786 1,965,878 A.N. “Jerry” Karabelas, Ph.D. 35,490,395 2,494,268 1,965,878 Daniel Tassé 35,984,653 2,000,010 1,965,878”
REGENXBIO Inc. reported financial results for the quarter ended March 31, 2023.
“On May 3, 2023, REGENXBIO Inc. (the “Company”) issued a press release regarding its results of operations and financial condition for the quarter ended March 31, 2023.”
REGENXBIO Inc. reported financial results for the quarter and year ended December 31, 2022.
“On February 28, 2023, REGENXBIO Inc. (the “Company”) issued a press release regarding its results of operations and financial condition for the quarter and year ended December 31, 2022.”
Curran M. Simpson was named as Chief Operating Officer at REGENXBIO Inc..
“On January 9, 2023, REGENXBIO Inc. (the “Company”) announced that Curran M. Simpson has been named Chief Operating Officer, effective immediately.”
REGENXBIO Inc. reported financial results for third quarter ended September 30, 2022.
“On November 3, 2022, REGENXBIO Inc. (the “Company”) issued a press release regarding its results of operations and financial condition for the quarter ended September 30, 2022.”
Jennifer Zachary was elected as Class I Director at REGENXBIO Inc..
“elected Jennifer Zachary as a Class I director of the Company and a member of the Audit Committee, effective immediately.”
Daniel J. Abdun-Nabi departed as Director at REGENXBIO Inc..
“On March 14, 2022, Daniel J. Abdun-Nabi notified REGENXBIO Inc. (the “Company”) that he will not stand for re-election as a director of the Company at the end of his current term, which expires at the Company’s 2022 annual meeting of stockholders.”
George V. Migausky was elected as Class III director at REGENXBIO Inc..
“On September 3, 2021, the Board, based upon the recommendation of the Nominating and Corporate Governance Committee, elected George V. Migausky as a Class III director of the Company and a member of the Audit Committee, effective immediately.”
Jean Bennett was elected as Class II director at REGENXBIO Inc..
“On September 3, 2021, the Board, based upon the recommendation of the Nominating and Corporate Governance Committee, elected Jean Bennett, M.D., Ph.D., as a Class II director of the Company and a member of the Nominating and Corporate Governance Committee, effective immediately.”
Luke M. Beshar resigned as Director at REGENXBIO Inc..
“On September 3, 2021, Luke M. Beshar notified REGENXBIO Inc. (the “Company”) of his resignation from the Board of Directors of the Company (the “Board”), effective immediately.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.